Latest news with #MohamedEzzEldin
Al Etihad
13-05-2025
- Health
- Al Etihad
ADPHC, Novartis Middle East sign MoU to enhance public health awareness, disease prevention in Abu Dhabi
13 May 2025 23:59 ABU DHABI (WAM)The Abu Dhabi Public Health Centre (ADPHC) has signed a Memorandum of Understanding (MoU) with Novartis Middle East FZE (Novartis), an Innovative Medicine company, to raise awareness, advance prevention, and improve disease management practices, particularly for cardiovascular diseases, diabetes, and chronic kidney disease in Abu Dhabi emirate. The MoU was signed by Rashed Obaid Alsuwaidi - Director General, representing ADPHC, and Mohamed Ezz Eldin, Head of GCC, representing Novartis, on May 13, during the 25th IUHPE World Conference on Health Promotion, which is taking place from May 13 to 16 , 2025, at the Abu Dhabi National Exhibition Centre (ADNEC). Dr. Rashed Obaid Alsuwaidi - Director General of ADPHC said, "This MoU is a vital step in our journey to strengthen public health systems and reduce the impact of non-communicable diseases in Abu Dhabi. We aim to deliver long-term, sustainable health outcomes for our population through strategic collaborations."Mohamed Ezz Eldin, Head of GCC at Novartis said, "We are proud to partner with the Abu Dhabi Public Health Centre in a mission that aligns with our commitment to advancing patient care. Together, we can reimagine medicine to ensure patients get the best care, and we believe we can make a measurable impact on people's lives through awareness, early detection, and proactive disease management."The strategic collaboration between the two entities highlights a mutual commitment to leveraging public health approaches with private sector innovation to promote healthier lifestyles and enhance community well-being in Abu the two-year agreement, ADPHC and Novartis will collaborate to create and execute awareness campaigns via digital and traditional channels, raising the public awareness about risk factors, early symptoms, and the significance of regular screenings for non-communicable collaboration is built around three strategic pillars:-Disease Awareness: Co-developing impactful campaigns to raise public awareness and educate communities about non-communicable diseases such as cardiovascular conditions, diabetes, and chronic kidney disease. These initiatives will leverage online and offline channels to encourage proactive health behaviours like routine testing.-Disease Prevention: Designing and implementing effective initiatives focused on the primary prevention of adult cardiovascular diseases, diabetes, and chronic kidney disease. Activities include targeted screening efforts to identify at-risk individuals early.-Best Practice Sharing in Disease Management: Collaborating to identify, share, and implement best practices across the patient journey. This includes early screening protocols, preventive strategies, and disease management models, drawing on global expertise amd best practices to enhance patient outcomes and improve healthcare system performance. The MoU also establishes a dedicated taskforce, with each party appointing a lead to coordinate efforts. The task force will meet regularly to align on project plans, assess feasibility, define key deliverables, and evaluate outcomes through jointly agreed key performance indicators (KPIs). The KPIs will be reviewed biannually to ensure alignment with strategic goals and to adapt to emerging public health needs.
Zawya
30-04-2025
- Health
- Zawya
Novartis and Emirates Dermatology Society renew strategic partnership to advance dermatological care in UAE
In an era of rapid medical innovation and information overload, diagnostic accuracy and clinical authenticity are crucial to eliminating delays, preventing misdiagnoses and ultimately enhancing patient outcomes Dubai, UAE – Novartis, a global leader in innovative medicines and the Emirates Dermatology Society (EDS) today announced the renewal of their partnership focused on revolutionizing dermatological care in the United Arab Emirates. Now entering its third year, the collaboration continues to prioritize high-impact immunological skin conditions such as Psoriasis, Hidradenitis Suppurativa (HS) and Chronic Spontaneous Urticaria (CSU) with a shared goal of closing diagnostic gaps and improving the quality of life for patients. While dermatology has made tremendous strides in the past few years, there is still an opportunity to accelerate the diagnosis and care for patients across the UAE. Beyond physical symptoms, conditions like Psoriasis, Hidradenitis Suppurativa and CSU often take a significant toll on patients' mental health, contributing to anxiety, depression and social isolation—underscoring the importance of timely, compassionate and comprehensive care. Chronic Spontaneous Urticaria (CSU) is a medical condition characterized by chronic hives that last for six weeks or longer. These hives can appear without an obvious trigger and may cause significant itching and discomfort. Hidradenitis Suppurativa (HS) is a chronic skin condition marked by recurrent, painful lumps or nodules under the skin. These lesions often become inflamed, can rupture, and may lead to scarring over time. Psoriasis is a chronic autoimmune skin disorder characterized by thick, red, scaly plaques on the skin. These lesions can be itchy, painful, and sometimes extensive. Together, Psoriasis, Hidradenitis Suppurativa (HS), and Chronic Spontaneous Urticaria (CSU) represent distinct chronic inflammatory skin diseases, each with unique clinical presentations and significant impact on quality of life. This partnership is focused on addressing these challenges with evidence-driven solutions that ensure faster, more accurate diagnoses and better treatment outcomes. 'The partnership with Novartis is about proactively addressing the barriers to care. We are committed to helping physicians recognize these conditions earlier, ensuring patients receive timely treatment and improving their overall well-being,' said Dr. Ayman Alnaeem, President, Emirates Dermatology Society. 'At Novartis, our commitment to reimagining medicine drives us to collaborate with organizations like EDS to advance dermatological care in the Gulf region. Together, we are building a healthcare ecosystem where timely, personalized care leads to better patient outcomes,' added Mohamed Ezz Eldin, Head of GCC, Novartis. The Emirates Dermatology Society (EDS) is not just a professional network—it is a leading force in shaping the future of dermatological care in the UAE. With an active management committee overseeing its activities, EDS plays a crucial role in connecting dermatologists, facilitating knowledge-sharing and promoting excellence in dermatology 'Our goal is to bring dermatologists together to collaborate, share insights and contribute to the ongoing evolution of care. This partnership allows us to turn discussions into action—translating global innovations into local solutions,' commented, Dr Raghda Al Maashari, Cultural Committee Chairperson, Emirates Dermatology Society. With this partnership, Novartis and EDS reaffirm their shared vision: a future where every patient has access to timely diagnosis, personalized treatment and a better quality of life. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.
